Drug profile

The FDA adverse-event record for Imidocarb Dipropionate Inj Sol

52 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Imidocarb Dipropionate Inj Sol. See the species affected, top reactions, and outcomes below.

52
adverse-event reports
21.2%
death-coded share
Dog
most-reported species
7
Death - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
52
Total Reports
11
Deaths Reported
21.2%
Death Rate

Active Ingredients

Imidocarb Dipropionate Inj Sol

Administration Routes

SubcutaneousIntramuscularUnknownOphthalmicOral

Species Affected

Dog 34
Cat 12
Human 2
Unknown 2
Horse 1
Other 1

Most Affected Breeds

Greyhound 12
Unknown 5
Domestic Shorthair 4
Domestic Mediumhair 4
Pit Bull 3
Crossbred Canine/dog 3
Retriever - Labrador 3
Siberian Husky 2
Dog (unknown) 2
Rottweiler 2

Most Reported Reactions

Death 7
Panting 5
Hypersalivation 5
Injection site lump 5
Gait abnormality 5
Neuropathy NOS 5
Tremor 4
Elevated alanine aminotransferase (ALT) 4
Elevated serum alkaline phosphatase (SAP) 4
Other abnormal test result NOS 4
Death by euthanasia 4
Injection site pain 4

Outcome Breakdown

Ongoing
20 (39.2%)
Recovered/Normal
13 (25.5%)
Outcome Unknown
7 (13.7%)
Died
7 (13.7%)
Euthanized
4 (7.8%)

Imidocarb Dipropionate Inj Sol Adverse Event Insights

52 reports name Imidocarb Dipropionate Inj Sol; 11 recorded a death outcome (21.2% of reported events, not a population-level mortality rate). Active ingredient: Imidocarb Dipropionate Inj Sol. Administration routes: Subcutaneous, Intramuscular, Unknown, Ophthalmic.

By species: Dog (34 reports), Cat (12 reports), Human (2 reports). By breed: Greyhound (12), Unknown (5), Domestic Shorthair (4).

Leading clinical signs: Death (7), Panting (5), Hypersalivation (5), Injection site lump (5). Outcome, 51 coded reports: Ongoing leads at 39.2%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.